| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 7, 2023 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
Completes business combination with Aesther Healthcare Acquisition Corp. Ocean Biomedical stock will trade on Nasdaq under ticker symbol "OCEA" Providence, RI and New York, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical ("the Company") (NASDAQ:OCEA), a next-generation biopharma company, today announced the completion of its business combination with Aesther Healthcare Acquisition Corp. ("Aesther") (NASDAQ:AEHA), a publicly traded special purpose acquisition company. Ocean Biomedical, Inc., the resulting combined company, is expected to commence trading on the Nasdaq Capital Market under the symbol "OCEA" on February 15, 2023. The business combination was approved by Aesther's sh
Multiple Patents granted for Methods and Composition for Mono-specific and Bi-specific antibody approaches that suppress tumors by targeting and neutralizing elevated levels of chitinase 3-like-1 (CHI3L1) and other mediators. Ocean Biomedical is expected to become a publicly traded company on the NASDAQ global market under the symbols "OCEA" and "OCEAW" following the closing of a Business Combination with Aesther Corporation Providence, RI and New York, NY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ:AEHA) announced today that Scientific Co-founder Dr. Jack A. Elias has been awarded multiple patents for his discoveries relat
NEW YORK and PROVIDENCE, R.I, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ:AEHA) ("Aesther"), a special purpose acquisition company ("SPAC") and Ocean Biomedical, Inc. ("Ocean"), a next-generation biopharma company, today announced that its stockholders approved all proposals related to the previously announced proposed business combination between Aesther and Ocean at a special meeting of stockholders held on February 3, 2023. A Form 8-K disclosing the full voting results is expected to be filed with the Securities and Exchange Commission. "I'm pleased that the majority of shareholders have, through their votes in favor of going public, reaffirmed t
4 - Ocean Biomedical, Inc. (0001869974) (Issuer)
4 - Ocean Biomedical, Inc. (0001869974) (Issuer)
4/A - Ocean Biomedical, Inc. (0001869974) (Issuer)
SC 13G - Ocean Biomedical, Inc. (0001869974) (Subject)
SC 13G/A - Ocean Biomedical, Inc. (0001869974) (Subject)
SC 13G/A - Ocean Biomedical, Inc. (0001869974) (Subject)